Updates are available Correction dated 2021-09-18
Click to view Correction: https://doi.org/10.1007/s11916-021-00985-w
-
Authors
Schwenk, Eric S. http://orcid.org/0000-0003-3464-4149
Pradhan, Basant
Nalamasu, Rohit
Stolle, Lucas
Wainer, Irving W.
Cirullo, Michael
Olson, Alexander
Pergolizzi, Joseph V.
Torjman, Marc C.
Viscusi, Eugene R.
- License Information
-
More Information
Article History
Accepted: 21 June 2021
First Online: 16 July 2021
Change Date: 18 September 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s11916-021-00985-w
Declarations
:
: Irving W. Wainer declares holding a patent assigned to U.S. Government, Department of Health and Human Services, National Institutes of Health, for which he may receive royalties.Joseph Pergolizzi discloses the following relationships: Consultant/ Speaker, Owner, and Researcher for Spirify, US World Meds, Salix, Enalare, Scilex, Pfizer, Lilly, Teva, Taketa, Regeneron, BDSI, Bridge Therapeutics Grunenthal, and Neumentum. Specific to ketamine include present consultant to Spirify Pharma.Marc Torjman reports a patient pending on the use of (2R,6R)-hydroxynorketamine, (S)-dehydronorketamine and other stereoisomeric dehydro- and hydroxylated metabolites of (R,S)-ketamine in the treatment of depression and neuropathic pain.Basant Pradhan, Lucas Stolle, Eric Schwenk, Alexander Olson, Rohit Nalamasu, and Michael Cirullo declare no conflict of interest.
: This article does not contain any studies with human or animal subjects performed by any of the authors.
